$ETSY

REIFF MELISSA sold $328K of ETSY

REIFF MELISSA sold 3,855 shares of ETSY INC (ETSY) at $85.00 ($0.33M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · REIFF MELISSA
Published Jul 17, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ETSY
Neutral
high confidence
Mentioned
$ETSY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETSYNeutralLow
01

Why it matters

The disclosure provides incremental information about insider activity but does not indicate a new fundamental development for ETSY.

02

Market read

Traders may monitor insider activity, but this specific transaction is routine and planned, so it is unlikely to drive a fundamental repricing.

03

What to watch

Director sales can be driven by diversification, taxes, or scheduled liquidity needs; the 10b5-1 plan suggests reduced informational content.

Relevance 3/10Novelty 3/10Timing: Filed July 17, covering a sale executed July 15.

Background

The article is an SEC Form 4 insider transaction filed by a director, reporting an open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ETSYNeutralHigh confidence
Context

SEC Form 4 shows director Melissa Reiff sold 3,855 shares of ETSY for about $327,675 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically muted for 10b5-1 sales.

Evidence & confidence

The filing is an insider transaction disclosure, not earnings, guidance, litigation, or a corporate action. The presence of a pre-arranged 10b5-1 plan reduces the signal of new information.

Market effects

No meaningful sector read-through; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Even planned sales can coincide with private views on valuation or liquidity needs, so some traders may still treat it as mild bearish sentiment.

Key entities

  • ETSY

    Company whose director insider sale is disclosed on Form 4.

  • REIFF MELISSA

    Director who sold 3,855 shares at $85.00/share on July 15, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WMTMed

Retailers Report AI-Driven Sales, Bigger Baskets in Q2 Earnings

Walmart, Amazon, and Target reported Q2 earnings showing AI-driven sales growth. Walmart's eCommerce grew 23%, with AI assistant users spending 40% more. Amazon's Alexa for Shopping saw active users nearly double. Target's digital traffic from AI platforms grew over 3.5x faster than the industry average. Albertsons saw a 10-26% increase in order value with AI tools. Shopify's AI-referred traffic and orders tripled, but AI's impact on discovery-driven retail remains uncertain.

$ETSYHigh

Bank of America Resets Etsy Stock Price Target After Event

Bank of America upgraded Etsy to Buy, raising its price target to $105 from $88, citing structural growth. The bank expects mid-single-digit gross merchandise sales growth, higher profitability, and increased shareholder returns. Etsy's new management team is seen as key to reinvigorating growth. BofA raised its fiscal 2027 estimates for gross merchandise sales, EBITDA, and EPS.

$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.